


IFW

Please Direct All Correspondence to Customer Number **20995**

**TRANSMITTAL LETTER**  
**INFORMATION DISCLOSURE STATEMENT**

Applicant : Higuchi, et al.  
App. No : 10/572,404  
Filed : March 16, 2006  
For : DRUG AND METHOD FOR  
PROLIFERATING NATURAL KILLER  
CELLS  
Examiner : Unknown  
Art Unit : Unknown

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

May 22, 2006

(Date)

*Che S. Chereskin*

Che Swyden Chereskin, Ph.D., Reg. No. 41,466

**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing 8 references for consideration. Eight references are enclosed.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

*Che S. Chereskin*


Che Swyden Chereskin, Ph.D.

Registration No. 41,466

Agent of Record

Customer No. 20,995

(949) 760-0404



## INFORMATION DISCLOSURE STATEMENT

Applicant : Higuchi, et al.  
App. No : 10/572,404  
Filed : March 16, 2006  
For : DRUG AND METHOD FOR  
PROLIFERATING NATURAL KILLER  
CELLS  
Examiner : Unknown  
Art Unit : Unknown

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 8 references to be considered by the Examiner. These eight references are provided..

WO 98/19675 is submitted as the English language equivalent for JP 2001-503430.

WO 98/33509 is submitted as the English language equivalent for JP 2002-515893.

All references include at least a partial translation in the English language.

This Information Disclosure Statement is being filed within three months of the filing date of the application no fee is required.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: May 22 2006

By: Che S. Chereskin

Che Swyden Chereskin, Ph.D.  
Registration No. 41,466  
Agent of Record  
Customer No. 20,995  
(949) 760-0404



PTO/SB/08 Equivalent

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Multiple sheets used when necessary)	Application No.	10/573,564
	Filing Date	March 27, 2006
	First Named Inventor	Kuhara, et al.
	Art Unit	Unknown
SHEET 1 OF 1	Examiner	Unknown
	Attorney Docket No.	TOYA108.014APC

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
		JP 2001-503430	03/13/01	Wisconsin Alumni Research Foundation		PCT 1 <sup>st</sup> Pg
		JP 2002-515893	05/28/02	Pharming B.V.		PCT 1 <sup>st</sup> Pg
		JP 2001-149069	06/05/01	Inst of Physical & Chemical Res		Abstract
		WO 98/19675	05/14/98	Wisconsin Alumni Research Foundation		
		WO 98/33509	08/06/98	Pharming BIV.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
		Porgador, et al. "Natural Killer Cell Lines Kill Autologous $\beta_2$ -Microglobulin-Deficient Melanoma Cells: Implications for Cancer Immunotherapy," <i>Proc. Natl. Acad. Sci., USA</i> , Vol. 94, pp. 13140-13145, 1997.	
		<i>Molecular Medicine</i> , Vol. 39, pp. 238-246, 2002.	Partial
		<i>Molecular Medicine</i> , Vol. 40, pp. 186-193, 2003.	Partial

2619649  
052206

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.